Do butyrate and other short-chain fatty acids support immune regulation and intestinal barrier integrity?

Short-chain fatty acids (SCFAs), particularly butyrate, are essential metabolites produced by the fermentation of dietary fiber that serve as primary signaling molecules for gut homeostasis and immune regulation.

Clinical and Mechanistic Evidence

Research confirms that butyrate is a fundamental driver of intestinal health through multiple pathways:

• Regulatory Immune Signaling: Butyrate promotes the differentiation of peripheral regulatory T cells (Tregs). It acts as a histone deacetylase (HDAC) inhibitor, which increases the expression of the FOXP3 gene—the master regulator for Treg function. This process enhances immune tolerance and suppresses the production of pro-inflammatory cytokines.
• Intestinal Barrier Integrity: Butyrate provides up to 70% of the energy requirements for colonocytes. It strengthens the physical barrier by upregulating tight junction proteins, such as ZO-1 and occludin, primarily through the activation of AMP-activated protein kinase (AMPK). This maintains the transepithelial electrical resistance (TEER) necessary to prevent "leaky gut" and the translocation of luminal antigens.

Mast Cell Regulation and Inflammation

Low levels of butyrate remove a critical inhibitory "brake" on the mucosal immune system, particularly regarding mast cell stability:

• Mast Cell Activation: Butyrate stabilizes mast cells by binding to the GPR109A receptor and inhibiting HDACs. This epigenetic regulation downregulates the high-affinity IgE receptor (FcεRI). When butyrate is low, mast cells become hyper-responsive, leading to increased degranulation and the release of histamine and tryptase.
• Mucosal Inflammation: The loss of butyrate-producing bacteria (such as Faecalibacterium prausnitzii) is a hallmark of mucosal inflammation. Without sufficient butyrate, the resulting mast cell activation and barrier breakdown create a feedback loop of chronic, low-grade inflammation often seen in inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS).

Bottom line

The claim is strongly supported: butyrate is vital for maintaining the intestinal barrier and promoting immune tolerance. Low levels directly contribute to mast cell instability and mucosal inflammation through the loss of GPR109A signaling and HDAC inhibition.